• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4618546)   Today's Articles (6458)   Subscriber (49402)
For: Elmas ÖF, Demirbaş A, Türsen Ü, Atasoy M, Lotti T. Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice. Dermatol Ther 2020;33:e14265. [PMID: 32882079 DOI: 10.1111/dth.14265] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 08/25/2020] [Accepted: 08/31/2020] [Indexed: 12/21/2022]
Number Cited by Other Article(s)
1
Wiedenmayer N, Vollmer AS, Winkler JK, Enk AH. Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects Using a Novel IVIg Preparation. Dermatol Ther (Heidelb) 2024;14:1969-1974. [PMID: 38865042 PMCID: PMC11265024 DOI: 10.1007/s13555-024-01191-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Accepted: 05/21/2024] [Indexed: 06/13/2024]  Open
2
Feng X, Zhou X, Zhang X, Xiao Y, Li F, Mi W, Gao J, Wang J, Zhou Y, Wang M, Wang W, Li W. Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study. Int Immunopharmacol 2024;135:112307. [PMID: 38796966 DOI: 10.1016/j.intimp.2024.112307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 04/28/2024] [Accepted: 05/16/2024] [Indexed: 05/29/2024]
3
Shirzad Moghadam F, Kianfar N, Dasdar S, Samii R, Farimani Z, Azar PM, Balighi K, Abedini R, Soori T, Salehi Farid A, Mahmoudi H, Daneshpazhooh M. Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: a historical cohort study. Dermatol Ther 2022;35:e15672. [PMID: 35768959 PMCID: PMC9349909 DOI: 10.1111/dth.15672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 06/22/2022] [Accepted: 06/25/2022] [Indexed: 11/28/2022]
4
Danieli MG, Piga MA, Paladini A, Longhi E, Mezzanotte C, Moroncini G, Shoenfeld Y. Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scand J Immunol 2021;94:e13101. [PMID: 34940980 PMCID: PMC8646640 DOI: 10.1111/sji.13101] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 08/31/2021] [Accepted: 09/08/2021] [Indexed: 12/15/2022]
5
Drenovska K, Vassileva S, Tanev I, Joly P. Impact of COVID-19 on autoimmune blistering diseases. Clin Dermatol 2021;39:359-368. [PMID: 34517993 PMCID: PMC7955939 DOI: 10.1016/j.clindermatol.2021.01.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
6
Bardazzi F, Abbenante D, Filippi F, Sacchelli L, Loi C. The initial experience of COVID-19 vaccination in autoimmune blistering diseases patients from a reference care center in Italy. Dermatol Ther 2021;34:e15057. [PMID: 34232544 PMCID: PMC8420445 DOI: 10.1111/dth.15057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 07/05/2021] [Indexed: 11/30/2022]
7
DEMİRBAŞ A, ELMAS ÖF, ATASOY M, ULUTAŞ DEMİRBAŞ G, TÜRSEN Ü, LOTTI T, KİLİTCİ A. A Case of COVID-19 in a patient with Pemphigus successfully managed with favipiravir. KONURALP TIP DERGISI 2021. [DOI: 10.18521/ktd.896761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
8
Sinagra JL, Vedovelli C, Binazzi R, Salemme A, Moro F, Mazzanti C, Didona B, Di Zenzo G. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. Front Immunol 2021;12:665522. [PMID: 33936104 PMCID: PMC8087171 DOI: 10.3389/fimmu.2021.665522] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 03/29/2021] [Indexed: 01/08/2023]  Open
9
Uzuncakmak TK, Özkoca D, Askin O, Kutlubay Z. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic? Dermatol Ther 2020;34:e14647. [PMID: 33296557 PMCID: PMC7883057 DOI: 10.1111/dth.14647] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 11/23/2020] [Accepted: 12/03/2020] [Indexed: 12/17/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA